ClinicalTrials.gg
Not yet recruitingNCT07246629Updated Oct 1, 2026

Lumbar Drain With Intrathecal Nicardipine in Aneurysmal Subarachnoid Hemorrhage

A Phase 4 interventional study of Normal Saline and Nicardipine in Subarachnoid Hemorrhage, sponsored by Wake Forest University Health Sciences. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Wake Forest University Health Sciences · Phase 4, Interventional, and Prevention

How we know

Updated Oct 1, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
214
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 149 studies in Subarachnoid Hemorrhage with a site in United States — 31 open to participants now, 37 under way, 2 of them phase 3. Subarachnoid Hemorrhage · United States.

Planned enrollment
16th of 107
214 · median 30
Started
2027
with 2 others
Phase 4
17 of 149
3 open now
Primary completion
2028-03
later than 22 of 36 live
Registered
142nd of 149
by date

Among the 149 studies in Subarachnoid Hemorrhage with a site in United States, this one is the 16th largest by planned enrollment of the 107 interventional ones that give a count, is one of 3 that started in 2027, is one of 17 in phase 4, reaches primary completion later than 22 of the 36 other live ones, and was the 142nd registered.

Subarachnoid Hemorrhage

513 studies on the registry are indexed under Subarachnoid Hemorrhage; 131 are open to participants now.

Browse Subarachnoid Hemorrhage studies →

Open to participants now

31 of the 149 studies in Subarachnoid Hemorrhage with a site in United States are open now. Recruiting first, the newest first:

26 more — sign in →

All 31 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 92 Subarachnoid Hemorrhage studies recruiting now, 58 (63%) set no upper age limit and 5 (5%) stop at 75 or younger; 8 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 149 studies in Subarachnoid Hemorrhage with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine the effectiveness of prophylactic administration of intra-thecal nicardipine though lumbar cerebrospinal fluid drain in prevention of symptomatic vasospasm in patients with subarachnoid hemorrhage due to rupture of cerebral aneurysms.

Read the detailed description

This is a triple-blinded, prospective, sham, randomized study. The purpose of this research is to determine the effectiveness of prophylactic administration of intra-thecal nicardipine though lumbar cerebrospinal fluid drain in prevention of symptomatic vasospasm in patients with subarachnoid hemorrhage due to rupture of cerebral aneurysms. Patients will be randomized to standard treatment of cerebral vasospasm with prophylactic administration of intrathecal nicardipine vs standard treatment alone. The medication used is FDA approved and will be used through an intra-thecal route through a lumbar drain which is indicated in patients with subarachnoid hemorrhage.

03

Conditions studied

  • Subarachnoid Hemorrhage

Keywords

  • cerebral aneurysm
  • intrathecal nicardipine
  • vasospasm
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • Aneurysmal subarachnoid hemorrhage with Hunt and Hess score 3 or less
  • Patient or legal authorized representative available to sign the form
  • Pre-morbid modified Rankin scale of 0 or 1.
  • Patients who have lumbar drain placed or planned for cerebrospinal fluid diversion per standard of care
  • Patients who are able to be randomized within 72 hours from arrival with aneurysmal subarachnoid hemorrhage or within 24 hours from lumbar drain placement

Exclusion criteria

Exclusion Criteria:

  • Pregnant females
  • Subarachnoid hemorrhage (SAH) with hunt and hess scale of >3
  • SAH due to etiology other than aneurysmal rupture
  • Any in patients receiving calcium channel antagonists like to dihydropyridines
  • Active central nerve infection (CNS) infection or high suspicion of CNS infection
  • Hemodynamic instability preventing the use of Nicardipine
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
214 participants (estimated)

Study arms

  • Sham comparator
    Standard of Care

    standard treatment of cerebral vasospasm and sham injection of 10 mL preservative-free normal saline in luer-lock sterile syringe

    Drug: Normal Saline

  • Experimental
    Standard of Care Plus Nicardipine

    standard treatment of cerebral vasospasm with prophylactic administration of intrathecal nicardipine

    Drug: Nicardipine

Interventions

  • DrugNormal Saline

    10 mL preservative-free normal saline in luer-lock sterile syringe every 24 hours from randomization through day 14 post-bleed or lumbar drain removal, whichever occurs first.

  • Nicardipine 4 mg will be diluted in preservative-free normal saline to 10 mL in luer-lock sterile syringe every 24 hours from randomization through day 14 post-bleed or lumbar drain removal, whichever occurs first.

06

What researchers measure

Primary outcomes

  1. Incidence of Vasospasm

    The incidence of symptomatic clinical or radiographic vasospasm in patients treated with prophylactic administration of intrathecal nicardipine though lumbar drain

    Time frame: up to hospitalization day 21

  2. Incidence of Delayed Cerebral Ischemia

    The incidence of symptomatic clinical or radiographic delayed cerebral ischemia in patients treated with prophylactic administration of intrathecal nicardipine though lumbar drain

    Time frame: up to hospitalization day 21

Secondary outcomes

  1. Modified Rankin Scale Score

    The Modified Rankin Scale is a clinical tool used to assess the functional disability after a stroke. It is a six-point ordinal scale that measures the patient's ability to perform activities of daily living. Score Range: 0 no symptoms, 1 no significant disability, 2 slight disability, 3 moderate disability, 4 moderately severe disability, 5 severe disability, 6 dead.

    Time frame: month 6

  2. Incidence of Meningitis

    Incidence of meningitis as confirmed by clinical and laboratory findings

    Time frame: up to hospitalization day 21

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Jan 2027; primary completion for Mar 2028, 14 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 1, 2026: start Sep 2026 → Jan 2027, primary completion Mar 2027 → Mar 2028 and completion Mar 2027 → Mar 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2025
First posted
Nov 24, 2025
StartEst.
Jan 2027was Sep 2026
Primary completionEst.
Mar 2028was Mar 2027
CompletionEst.
Mar 2028was Mar 2027
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 2026→Jan 2027
Oct 1, 2026
Primary completion
Mar 2027→Mar 2028
Oct 1, 2026
Study completion
Mar 2027→Mar 2028
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Start date Sep 2026→Jan 2027
    Primary completion Mar 2027→Mar 2028
    Study completion Mar 2027→Mar 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07246629
Responsible party
Sponsor
First posted
Nov 24, 2025
Start date
Jan 2027 (estimated)
Primary completion
Mar 2028 (estimated)
Completion
Mar 2028 (estimated)
Last update
Oct 1, 2026

Study contacts

Sajid Suriya, MD
Contact
Sajid.suriya@aah.org
847-723-2078
Krishna Joshi, MD
principal investigator · Advocate Lutheran General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nicardipine

Start the discussion